CMAX Clinical Research

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on IHL-42X, the company’s proprietary drug product for treatment of obstructive sleep...

Biopharma company developing next-generation mental health treatments Bright Minds Biosciences Inc. (NASDAQ: DRUG) has closed its overnight offering for gross proceeds of approximately $4 million. The company also announced it will start dosing patients in the trial of...

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary multi-use, anti-inflammatory drug IHL-675A. IHL-675A is a combination cannabinoid drug comprising...